J. Gauthier, C. Turtle
tlooto Summary
The clinical presentations of CRS and neurotoxicity in a cohort of 133 adults treated with CD19 CAR-T cells at Fred Hutchinson Cancer Research Center are described, and insights are provided into the mechanisms contributing to these toxicities.
Abstract
T-cells engineered to express CD19-specific chimeric antigen receptors (CD19 CAR-T cells) can achieve high response rates in patients with refractory/relapsed (R/R) CD19+ hematologic malignancies. Nonetheless, the efficacy of CD19-specific CAR-T cell therapy can be offset by significant toxicities, such as cytokine release syndrome (CRS) and neurotoxicity. In this report of our presentation at the 2018 Second French International Symposium on CAR-T cells (CAR-T day), we describe the clinical presentations of CRS and neurotoxicity in a cohort of 133 adults treated with CD19 CAR-T cells at Fred Hutchinson Cancer Research Center, and provide insights into the mechanisms contributing to these toxicities.
Citation format
GAUTHIER, J.; TURTLE, C. Insights into cytokine release syndrome and neurotoxicity after cd19-specific CAR-T cell therapy. Current Research in Translational Medicine, 2018, 66: 50–52.